Clinical Trials
3 trialsNCT04841811 2026-05-22
APPROACH
Guangdong Association of Clinical Trials
Phase 3 Active not recruiting
NCT04923906 2024-11-25
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04687241 2024-11-07
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting